In the US, Clofazimine (clofazimine systemic) is a member of the drug class leprostatics and is used to treat Leprosy, Leprosy - Dapsone-Resistant, Leprosy - Dapsone-Sensitive and Leprosy - Erythema Nodosum Leprosum.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
- Clofaziminum (Latin)
- Clofazimin (German)
- Clofazimine (French)
- Clofazimina (Spanish)
- Clofazimine (OS: USAN, BANM, JAN)
- B 663 (IS)
- G 30320 (IS)
- NSC 141046 (IS)
- Riminophenazine (IS)
- Clofazimine (PH: BP 2016, Ph. Eur. 8, Ph. Franç. 11, Ph. Int. 4, USP 38)
- Clofaziminum (PH: Ph. Eur. 8, Ph. Int. 4)
- Clofazimine Swiss Pharma
Swiss Pharma, Georgia
- Clofazimine-Liye Pharm
Nanjing Liye Pharmaceutical, China
Novartis, Netherlands; Sandoz, Japan
Novartis, Egypt; Novartis Pharmaceuticals, Australia
|BANM||British Approved Name (Modified)|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.